Take a look back at the top chronic lymphocytic leukemia news from 2019

Issue: December 25, 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In this supplement to HemOnc Today, we compiled the most-read articles about chronic lymphocytic leukemia from this year. From FDA news for breakthrough designations and approvals to success with new combination therapies, our experts researched and weighed in on the changing spectrum of this disease and what the advancements mean for patients.

“The standard of care for frontline CLL has shifted from chemoimmunotherapy,” Ian W. Flinn, MD, PhD, oncologist at Sarah Cannon Research Institute/Tennessee Oncology, told HemOnc Today. “The advantage of [a combination] regimen is that you can get people off of treatment in over a year. That’s really exciting for patients because now they won’t have to stay on treatment indefinitely.”

To follow along this journey, be sure to follow @HemOncToday on Twitter and visit Healio.com regularly.

Click here to view the interactive PDF and visit the Leukemia newsfeed for the latest CLL news.